BRPI0815658A2 - Aril-éter pirrolidina como antagonistas do receptor nk3 - Google Patents

Aril-éter pirrolidina como antagonistas do receptor nk3

Info

Publication number
BRPI0815658A2
BRPI0815658A2 BRPI0815658-1A2A BRPI0815658A BRPI0815658A2 BR PI0815658 A2 BRPI0815658 A2 BR PI0815658A2 BR PI0815658 A BRPI0815658 A BR PI0815658A BR PI0815658 A2 BRPI0815658 A2 BR PI0815658A2
Authority
BR
Brazil
Prior art keywords
pyrolidine
receptor antagonists
aryl ether
aryl
ether
Prior art date
Application number
BRPI0815658-1A2A
Other languages
English (en)
Inventor
Philippe Jablonski
Kenichi Kawasaki
Henner Knust
Anja Limberg
Matthias Nettkoven
Hasane Ratni
Claus Riemer
Xihan Wu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0815658A2 publication Critical patent/BRPI0815658A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
BRPI0815658-1A2A 2007-08-07 2008-07-29 Aril-éter pirrolidina como antagonistas do receptor nk3 BRPI0815658A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07113942 2007-08-07
PCT/EP2008/059908 WO2009019163A1 (en) 2007-08-07 2008-07-29 Pyrrolidine aryl-ether as nk3 receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0815658A2 true BRPI0815658A2 (pt) 2015-02-18

Family

ID=39865446

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815658-1A2A BRPI0815658A2 (pt) 2007-08-07 2008-07-29 Aril-éter pirrolidina como antagonistas do receptor nk3

Country Status (19)

Country Link
US (1) US8012998B2 (pt)
EP (1) EP2185540B1 (pt)
JP (1) JP2010535733A (pt)
KR (1) KR101167774B1 (pt)
CN (1) CN101778837A (pt)
AR (1) AR067808A1 (pt)
AT (1) ATE517100T1 (pt)
AU (1) AU2008285718A1 (pt)
BR (1) BRPI0815658A2 (pt)
CA (1) CA2695211A1 (pt)
CL (1) CL2008002293A1 (pt)
ES (1) ES2367464T3 (pt)
IL (1) IL203363A (pt)
MX (1) MX2010001080A (pt)
PE (1) PE20090898A1 (pt)
RU (1) RU2010106974A (pt)
TW (1) TW200916456A (pt)
WO (1) WO2009019163A1 (pt)
ZA (1) ZA201000676B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008290634B2 (en) * 2007-08-22 2012-12-06 F. Hoffmann-La Roche Ag Pyrrolidine aryl-ether as NK3 receptor antagonists
EP2391615B1 (en) 2009-01-30 2013-01-16 F. Hoffmann-La Roche AG Piperidine derivatives as nk3 receptor antagonists
US8318759B2 (en) * 2009-02-18 2012-11-27 Hoffmann-La Roche Inc. Pyrrolidine derivatives as NK3 receptor antagonists
US8394834B2 (en) * 2009-08-25 2013-03-12 Hoffman-La Roche Inc. Pyrrolidines as NK3 receptor antagonists
CA2776480A1 (en) * 2009-10-20 2011-04-28 Pfizer Inc. Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators
US8507535B2 (en) 2010-07-07 2013-08-13 Hoffmann-La Roche Inc. Methyl-pyrrolidine ether derivatives
CN107108581B (zh) 2014-08-21 2020-06-23 百时美施贵宝公司 作为强效rock抑制剂的回接苯甲酰胺衍生物
MA43313B1 (fr) 2015-09-02 2022-06-30 Trevena Inc Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides
CN105399661A (zh) * 2015-12-14 2016-03-16 华东师范大学 2,6-二溴甲基吡啶的制备方法
JP6710273B2 (ja) * 2016-05-09 2020-06-17 日本曹達株式会社 環状アミン化合物および有害生物防除剤
CN110446495B (zh) 2017-02-17 2023-09-05 特维娜有限公司 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
CN110520129A (zh) * 2017-02-17 2019-11-29 特维娜有限公司 含有5元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
WO2021030335A1 (en) * 2019-08-12 2021-02-18 Millendo Therapeutics, Inc. A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof
CN116406268A (zh) 2020-10-27 2023-07-07 特维娜有限公司 δ-阿片样物质调节剂的结晶和无定形形式

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU506399B2 (en) 1975-12-30 1980-01-03 Showa Denko Kabushiki Kaisha 3-(2-aryl-2-propyl) ureas
IN148482B (pt) 1977-06-03 1981-03-07 Pfizer
GB9321557D0 (en) 1992-11-03 1993-12-08 Zeneca Ltd Carboxamide derivatives
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
IL112134A (en) 1993-12-29 1999-12-22 Merck Sharp & Dohme Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
GB9714129D0 (en) * 1997-07-04 1997-09-10 Pfizer Ltd Azetidines
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
EP1192952A3 (en) 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
HK1085462A1 (en) * 2002-05-31 2006-08-25 Takeda Pharmaceutical Company Limited Piperidine derivative, process for producing the same, and use
ES2291891T3 (es) 2003-07-03 2008-03-01 F. Hoffmann-La Roche Ag Antagonistas duales de nk1/nk3 para tratamiento de esquizofrenia.
JP2007507504A (ja) * 2003-09-30 2007-03-29 メルク　エンド　カムパニー　インコーポレーテッド フェニルピロリジンエーテル系タキキニン受容体拮抗薬
WO2005068427A1 (ja) * 2004-01-14 2005-07-28 Takeda Pharmaceutical Company Limited カルボキサミド誘導体およびその用途
US7138423B2 (en) * 2004-07-20 2006-11-21 Bristol-Myers Squibb Company Arylpyrrolidine derivatives as NK-1 /SSRI antagonists
KR100939347B1 (ko) 2005-07-20 2010-01-29 (주)카이로드 광학적으로 순수한 (ｓ)-3-히드록시 피롤리딘의 제조방법

Also Published As

Publication number Publication date
CN101778837A (zh) 2010-07-14
WO2009019163A1 (en) 2009-02-12
TW200916456A (en) 2009-04-16
EP2185540B1 (en) 2011-07-20
ZA201000676B (en) 2010-10-27
EP2185540A1 (en) 2010-05-19
IL203363A (en) 2013-03-24
JP2010535733A (ja) 2010-11-25
PE20090898A1 (es) 2009-07-13
US8012998B2 (en) 2011-09-06
RU2010106974A (ru) 2011-09-20
MX2010001080A (es) 2010-03-01
KR101167774B1 (ko) 2012-07-24
KR20100045502A (ko) 2010-05-03
AR067808A1 (es) 2009-10-21
US20090042896A1 (en) 2009-02-12
CL2008002293A1 (es) 2009-05-29
ES2367464T3 (es) 2011-11-03
ATE517100T1 (de) 2011-08-15
AU2008285718A1 (en) 2009-02-12
CA2695211A1 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
BRPI0815674A2 (pt) Aril-éter de pirrolidina como antagonista de receptor de nk3
HUS2200033I1 (hu) CGRP receptor antagonisták
ATE517100T1 (de) Pyrrolidinarylether als nk3-rezeptorantagonisten
BRPI0821141A2 (pt) Derivados de heteroarila como antagonistas do receptor de orexina
DK2821407T3 (da) Piperidinoncarboxamidazaindan-cgrp receptorantagonister
CR10926A (es) Nuevas 2-aminooxazolinas como ligandos taar1
BRPI0909157A2 (pt) compostos heterocíclicos como antagonistas de receptores de adenosina
EP2350060A4 (en) Melanocortin receptor AGONISTS
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
BRPI0810462A2 (pt) Derivados de quinolina-carboxamida como antagonistas de p2y12
BRPI1013821A2 (pt) piridinas substituídas como antagonistas de ccr3.
DK2448963T3 (da) T-celle receptorer
CR20130271A (es) Antagonistas de mdm2 de espiro-oxindol
BRPI0919844A2 (pt) compostos de azaindazol como antagonistas do receptor ccr1
BRPI1013856A2 (pt) terapias à base de ligantes de receptores quimiossensíveis
BRPI0814806A2 (pt) Pirazinas substituídas como antagonistas de cb1
BRPI1016189A2 (pt) compostos de 4-azetidinil-1-fenil-ciclohexano antagonistas de ccr2
BRPI0717023A2 (pt) Tiazol pirazolopirimidina como antagonistas do receptor de crf1
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
HRP20150167T1 (xx) Spojevi kao antagonisti bradikinina-b1
BRPI0815948A2 (pt) "compostos heterocíclicos como antagonistas de receptorncrth2"
HUE063115T2 (hu) Kiméra I-es típusú IL-1 receptor antagonisták
BR112012003701A2 (pt) "novos antagonistas de quinolina-hepcidina"
EP2176386A4 (en) UPPER CARBURETOR

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.